Becoming a Champion Go Player
Although antibodies, at the time of writing, still dominate the clinic, there is a definite shift in the drug development pipeline towards more “complex”, next-generation molecules. The array of new formats for the NGB sector is bewildering. Any expression platform developed must therefore address general needs arising from such engineered proteins rather than the needs of a specific molecule type. It is likely that such an expression platform will actually comprise a toolbox of solutions for scientists to get the best chance of translating their idea into reality.
When One Size Doesn't Fit All
Biologic pipelines are evolving towards more complex and difficult to express formats. Bispecific and other novel antibody formats or glycoproteins, often have domains combined from different molecules and unnatural engineered elements which can prove challenging for traditional expression platforms. Next generation protein expression will require a toolbox of next generation solutions.
Challenges of Manufacturing the Expanding Range of Bi/Multispecific Modalities
The pharmaceutical industry is increasingly focused on the development of next-generation drug products that allow the targeted delivery of active ingredients with multiple functionalities, increasing both efficacy and safety. Bi- and multispecific antibodies are prime examples of new drug substances with the potential to offer higher potency combined with new mechanisms of action while also reducing the cost and time for drug development.